TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02108223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fix dose r-FSH (Gonal-f)
Description: recombinant follicle stimulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-LH supplementation
Description: recombinant luteinizing hormone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-FSH (Gonal-f)
Description: recombinant follicle stimulation hormone
Study: NCT03962634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kovanaze Nasal Spray
Description: Intra-nasal local anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine Injection
Description: Local anesthetic
Study: NCT00704392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL647
Description: Tablets supplied at 50-mg strength administered orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147
Description: Gelatin capsules supplied at 25-mg and 100-mg strengths administered orally daily
Study: NCT01063504

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: teriparatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide
Study: NCT04695418

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rice Germ
Description: The rice germ was taken every day (25 g in the morning with breakfast and 25 g in the afternoon as snacks) for four weeks

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An isocaloric wheat germ-based supplement was taken every day (25 g in the morning with breakfast and 25 g in the afternoon as snacks) for four weeks
Study: NCT01255189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: near infrared spectroscopy: INVOS 5100
Description: NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: invos 5100
Description: near infrared spectroscopy: invos 5100
Study: NCT02667028

Intervention type: PROCEDURE
Intervention: PCI
Description: percutaneous coronary intervention
Study: NCT01766245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: For subcutaneous (s.c., under the skin), single dose administration at two separate dosing visits.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: For subcutaneous (s.c., under the skin), single dose administration at two separate dosing visits.
Study: NCT01597440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-carbamylglutamate
Description: Active NCG \& Standard of Care Chemical Composition: N-carbamyl-L-glutamic acid (NCG) The daily dose will be 100 mg/kg/ day. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube (standard of care will prevail when choosing the mode of drug administration).~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.~This drug will be administered for 7 days after admission or until discharge (whichever is sooner).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study: NCT02809118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-111 0.4 mg/ml
Description: AM-111 0.4 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-111 0.8 mg/ml
Description: AM-111 0.8 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel is administered with a single dose into the affected ear after topical anesthesia
Study: NCT00798473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Zoledronic acid 0.066 mg/kg (maximum 4 mg) given as a single intravenous infusion over ten minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV saline infusion
Study: NCT01591993

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 10% lactic acid test
Description: To each subject, 10% lactic acid is applied to one nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To each subject, 0.9% saline solution will be applied to the contralateral nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
Study: NCT04055844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 10 days of decitabine 20 mg/m2 IV daily; or, alternatively, per institution, physician, or patient preference on a 5-2-5 schedule with no weekend infusion. If a CR is achieved after 2 cycles using the 10-day schedule, subsequent cycles will change to a 5-day schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Starting with day 1 of cycle 1 and continuing for up to 6 months after the end of the last cycle, patients will receive ruxolitinib 5 mg twice daily orally. Dose may be increased to 10 mg twice daily in cycles 2 through 4 if platelets improve to \>100 x 10\^9/L.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: DLI from the original donor will be infused within 10 days after the last dose of decitabine in each cycle.
Study: NCT02680106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPINNER
Description: The SPINNER device is aimed at the DSW from a distance of 20 cm and activated for 1 minute. A nano-fibrous matrix is thus created.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JELONET / IBU Biatain
Description: The patient's DSW will be dressed by JELONET/IBU Biatain
Study: NCT02429349

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Surgical Procedures- Unilateral oophorectomy will be performed by laparoscopy prior to undergoing chemo-radiation treatment as specified above. Subsequent ovarian cortex autotransplant will be performed by laparoscopy after the patients have been declared cured by their physicians.
Study: NCT00481221

Intervention type: PROCEDURE
Intervention: Observation of results from laboratory tests
Description: Laboratory data summary only
Study: NCT03346291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counseling
Description: individual, weekly, smoking cessation counseling + over-the-counter nicotine patch
Study: NCT05434936

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oophorectomy
Description: Patients undergoing surgery for any indicated procedure for fertility-threatening treatment will have attempt at collecting ovarian tissue at time of surgery.
Study: NCT02091193

Intervention type: DIETARY_SUPPLEMENT
Intervention: Krill Oil (Supplement A)

Intervention type: DIETARY_SUPPLEMENT
Intervention: Krill Oil (Supplement A)

Intervention type: DIETARY_SUPPLEMENT
Intervention: Placebo (Supplement B)

Intervention type: DIETARY_SUPPLEMENT
Intervention: Placebo (Supplement B)
Study: NCT04006067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: changing surgical gloves
Description: All the surgical team including surgeons, surgical assists and scrub technicians replaced their outer surgical gloves with a new pair of sterile gloves just prior to abdominal closure.
Study: NCT01844427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine HCl is an NMDA antagonist currently FDA approved for the treatment of moderate to severe Alzheimer's-type dementia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03713827

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tooth restoration
Description: restoration of non carious cervical lesions with two different restorative materials

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tooth restoration
Description: restoration of non carious cervical lesions with two different restorative materials
Study: NCT06216106

Intervention type: PROCEDURE
Intervention: Prepectoral breast reconstruction with polyurethane implants
Description: Breast reconstruction in the prepectoral plane without elevate the pectoralis major muscle. We choose this type of reconstruction only in patients with mastectomy flap thickness of plus then 0.5 cm. We usally use silicone implants covered by an external layer of polyurethane so not to put directly in contact the silicone with the subcutaneus tissue.
Study: NCT02558283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM® VOLIFT® with Lidocaine
Description: JUVÉDERM® VOLIFT® with lidocaine injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM® VOLIFT® with Lidocaine
Description: JUVÉDERM® VOLIFT® with lidocaine injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane®
Description: Restylane® injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane®
Description: Restylane® injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
Study: NCT02705222

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D&C
Description: Cervical dilatation and fractional endometrial curettage will be done in operation theatre and the curetting will be sent for histopathological examination

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopy
Description: Hysteroscopy will be done in operation theatre and hysteroscopic-guided curettings will also be taken and sent for histopathological examination
Study: NCT01570205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG-102
Description: single intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG-102
Description: single intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XG-102
Description: single intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XG-102
Description: single intravenous infusion
Study: NCT01529450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225
Description: 800-mg (4 200-mg capsules/day) capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225
Description: 800-mg (4 200-mg capsules/day) capsule
Study: NCT03630016

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulse oximetry with Owlet BabySat v1.0 sensor
Description: A comparative, single-center, non-randomized study to evaluate the SpO2 accuracy guidelines for pulse oximetry over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison with Owlet BabySat v1.0 and Owlet Smart Sock 2 sensors

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulse oximetry with Owlet BabySat v1.0 sensor
Description: A comparative, single-center, non-randomized study to evaluate the SpO2 accuracy guidelines for pulse oximetry over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison with Owlet BabySat v1.0 and Owlet Smart Sock 2 sensors

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pulse oximetry with Owlet BabySat v1.0 sensor
Description: A comparative, single-center, non-randomized study to evaluate the SpO2 accuracy guidelines for pulse oximetry over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison with Owlet BabySat v1.0 and Owlet Smart Sock 2 sensors
Study: NCT03013959

Intervention type: DRUG
Intervention: Pranoprofen
Description: it is an NSAIDs.As is reported, NSAIDs(pranoprofen) eye drops can suppress herpes simplex virus（HSV-1） reactivation and reduce inflammatory reaction in vitro and in vivo. In Clinical, there is no risk of corneal tissue melting, glaucoma, cataract by topical application of NSAIDs.

Intervention type: DRUG
Intervention: Pranoprofen
Description: it is an NSAIDs.As is reported, NSAIDs(pranoprofen) eye drops can suppress herpes simplex virus（HSV-1） reactivation and reduce inflammatory reaction in vitro and in vivo. In Clinical, there is no risk of corneal tissue melting, glaucoma, cataract by topical application of NSAIDs.
Study: NCT03797690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous needle aponeurotomy
Description: It consists in cutting the fibrotic cord due to the disease and responsible for the flexion contracture, with a needle under local anesthesia. The procedure can be repeated as required during the same session. One to three sessions with at least one-week interval are usually sufficient and will be allowed. It will be performed in outpatient setting by a senior physician experienced in the procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open surgery with limited aponeurectomy
Description: It consists in excision of the fibrotic aponeurosis.It will be performed by hand surgeons under loco-regional anaesthesia during a short hospitalization (1 day stay). Post-operative cares are necessary (analgesics, splint, nursing, physiotherapy)
Study: NCT03512119

Intervention type: DRUG
Intervention: Lumacaftor-Ivacaftor treatment
Description: Lumacaftor-Ivacaftor treatment during one year
Study: NCT03422016

Intervention type: DIAGNOSTIC_TEST
Intervention: electroretinogram (ERG)
Description: an ERG is a measure of the eyes response to a flash of light

Intervention type: DIAGNOSTIC_TEST
Intervention: electroretinogram (ERG)
Description: an ERG is a measure of the eyes response to a flash of light
Study: NCT01313468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 x 4 minute interval
Description: 1 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 x 4 minutes Intervals
Description: 4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate continuous Training
Description: 47 minutes of Moderate continuous Training
Study: NCT02283983

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cooling helmet
Study: NCT01523990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-2349
Description: Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.
Study: NCT02502279

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Engström Datex-Ohmeda ICU Ventilator
Description: patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Engström Datex-Ohmeda ICU Ventilator
Description: patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative CPAP mask
Description: patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation and a CPAP mask will be applied immediately postoperative.
Study: NCT04317859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Activation
Description: Behavioural Activation (BA) is a therapy previously shown to be effective in depressive disorders. This form of therapy involves modification of activities in order to change perceptions of specific situations, thereby improving mood. The BA treatment program will consist of 18 two-hour visits over 14 weeks (twice weekly group visits for the first 8 weeks, followed by two individual visits over 6 weeks).
Study: NCT01387074

Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
Study: NCT02849184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Description: Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.
Study: NCT01523990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-2349
Description: Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-2349
Description: Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-2349
Description: Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.
Study: NCT03155997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Adjuvant Endocrine Therapy
Description: Administered according to label instructions.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard Adjuvant Endocrine Therapy
Description: Administered according to label instructions.
Study: NCT04694846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Given NRT via trans-dermal patch, gum, nasal spray, inhaler or lozenges

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Hydrochloride Controlled-release
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Given PO
Study: NCT02849184

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily before bedtime.
Study: NCT03809156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat Oral Product
Description: Dual therapy of Riociguat and Ambrisentan at initiation of treatment.
Study: NCT02231489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Tablet
Description: Participants will receive 10 mg of JNJ-42756493 tablet as single oral dose on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Tablet
Description: Participants will receive 10 mg of JNJ-42756493 tablet as single oral dose on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Capsule
Description: Participants will receive 10 mg of JNJ-42756493 capsule as single oral dose on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Capsule
Description: Participants will receive 10 mg of JNJ-42756493 capsule as single oral dose on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61818549
Description: Participants will JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, after 2 hours of administration of JNJ-42756493 tablet/capsule on Day 1 Treatment Period 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61818549
Description: Participants will JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, after 2 hours of administration of JNJ-42756493 tablet/capsule on Day 1 Treatment Period 1.
Study: NCT03058302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CETA (Common Elements Treatment Approach)
Description: The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CETA (Common Elements Treatment Approach)
Description: The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
Study: NCT01155791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV 75 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biosyn
Description: IV dosage varies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5mg, orally